





# An Initiative for Speeding Innovation

2023

#### A Comprehensive Global Response to a Growing Threat



Our Focus on Driving Alzheimer's Innovations

Build a global cohort with high-quality, detailed data on a well-characterized, diverse population, readily **Global Cohort Diversity** available to researchers, to increase discovery of **Development** targets for drug development with associated Reduce the cost and time to bring new treatments **Global Clinical Trials** Speed to market globally Facilitate the implementation of national, regional **Healthcare System Patient** and global commitments to provide access to **Preparedness** future innovations in treatment, diagnosis and care access





#### A Comprehensive Global Response



Our Approach to Speeding Innovation











#### Addressing Global Unmet Needs A Track Record of Spurring Innovation





CEPI



Funds increased access to immunizations

Funds vaccines research for emerging infectious diseases

Funds innovation in Alzheimer's disease

\$900M launch \$19B to date \$750M launch \$2B to date \$750M goal at launch

2000

2021







#### The Davos Alzheimer's Collaborative



#### **Taking the Next Step to Respond to Global Commitments**

2013



Ministers from each of the G7 countries committed to a 12-point plan to set an ambition goal to speed innovation. 2017



Set a global action plan at the World Health Assembly aimed at making a difference to the lives of people affected by dementia. 2019



G20 commits to promote healthy and active ageing and implement comprehensive set of policies to address dementia.

2020



Presentation during the 2020
Annual Meeting in Davos
charges WEF and CEOi to
develop a multi-year
collaborative to change the
pace of innovation in
Alzheimer's disease research
and care

2021



A \$700+M collaboration announced

Link:
<a href="http://www3.weforum.org/docs/wef-The Davos Agenda">http://www3.weforum.org/docs/weforum.org/weforum.org/docs/weforum.org







#### A Comprehensive Global Response



Approximate Expense Budget for Programs

			Foundational Phase (2021-2022)	2023-2026	Total
Global C Develop		Goal  Build a global cohort with high-quality, detailed data on a well-characterized, diverse population to increase discovery of targets for drug development and identify associated biomarkers	\$10M	\$355M	\$365M
2 Global C	Clinical Trials	Goal  Build a global platform and network to reduce the cost and time to bring new treatments to market globally	\$3M	\$242M	\$245M
3 Healthca Prepare	are System dness	Goal  Facilitate the implementation of global commitments to provide access to future innovations in treatment, diagnosis and care	\$10M	\$90M	\$100M
					\$710M





#### Global Cohort Development



#### Global Cohort Development Program





## The Issues We Face

- Incomplete global understanding of the heterogeneity and the variability of Alzheimer's etiology
- Need for new targets and biomarkers for drug development



Our Commitment

 Build a global cohort of 1 million people with high-quality, detailed data on a wellcharacterized, diverse population, readily available to researchers, to increase discovery of targets for drug development with associated biomarkers







#### Global Cohort Development Program

Select Accomplishments to Date



Scale



Enrich Cohorts
Around the
World

Secured participation from 23 cohorts representing over 130,000 people and partnership with 22+ cohorts in a network in Europe and South America.

Completed trans-ethnic AD **Polygenic Risk Score** pilot.

Diversity



Prioritize Low to Middle Income Countries

Initiated digital phenotyping in Malaysia and Argentina.

**Broad Data Access** 



Decentralize Data
Access

Partnership with Gates Ventures'-funded **ADDI**.

**New Tools** 



Increase Data
Collection Methods

Reviewing potential leapfrog technologies (e.g., eye scanning, breath analysis, etc.).



# Healthcare System Preparedness



#### Healthcare System Preparedness





The Issues
We Face



Our Commitment

- The aging global population, which increases the number of families with Alzheimer's, has a dramatic impact on national budgets, global economic growth and monetary policy
- Healthcare systems are not prepared to detect cognitive change, diagnose accurately, identify the right intervention or deliver future treatment

 Facilitate the implementation of national, regional and global commitments to provide access to future innovations in treatment, diagnosis and care





#### **Patient Pathway**



DAC Intends to Catalyze and Scale Innovation Across the Individual and Family Journey

**Prevention Health Promotion Integrated Healthcare Long Term Care Encourage Targeted Innovation Awareness and Activation HCS Patient Flow Access** Consumer Healthcare Awareness & Mgmt and **Initial Focus** Activation Delivery Consumer **Screening** Diagnosis of Care Dementia **Public Awareness** & HCS/ MCI and and early **Planning** Care & Education **Payer** detection dementia Connection HCP Education & **Services** and Social Support Activation





#### Healthcare System Preparedness Program

Select Accomplishments to Date



Flagship Projects



Design and Implement Pilots

7 pilots in 6 countries created – focused on disease **detection**.

Japan, Jamaica, UK, Mexico, Brazil and the US (2). **Locally Driven Pilots** 



**Crowdsource Innovation** 

\$4.5M RFP issued – focused on **detection** – which is funding 12 programs across the globe.

Communities of Practice



Facilitate and Embed Change

Monthly meetings
held with flagship
sites to share
learnings and
problem solve
ultimately develop a
durable tool kit for
agile scaling.

Learning Labs



**Drive Adoption of Best Practices** 

Bi-annual meeting of governments and healthcare system executives initiated and metrics established to drive accountability.







#### Global Clinical Trials Support Platform



#### Global Clinical Trial Network Program





## The Issues We Face

 Clinical trials for Alzheimer's disease therapies are long, slow and expensive – delaying getting treatments to patients and providing care for those impacted by the disease.



Our Commitment

- Build and activate regional and global clinical trial networks and design advanced clinical trials that reduce the time, cost and improve the quality of AD clinical trials.
- Work with the other DAC initiatives to catalyze recruitment for clinical trials and development of reliable digital and blood biomarkers.





#### Clinical Trials Program

Select Accomplishments to Date



GAP European Network




Design and **Engage Sites** 

30 sites committed



Scale w/Scottish NHS



Design Clinical Trial Referral System w/Scottish NHS

Currently negotiating MOU with Scottish NHS, Scottish memory clinics and Scottish/EUR trial network

**Transatlantic Trials** 



**Design Transatlantic Trials with Sponsors** 

Secured 1 Therapeutic study and Biomarker study for use of NA/EUR Network **ROW Trials** 



Mapping additional countries to add to CT Network

In discussions with Site Networks in Australia, China, Japan, Singapore, South Korea







#### **Thank You**

**George Vradenburg** 

Vradenburg@aol.com

+1 202 414 0771

**Drew Holzapfel** 

dholzapfel@highlanterngroup.com

+1 703 599 9617

